 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...56789101112131415...123124» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Metastases: Clinical comparative study of lenvatinib sequential iodine-131 and traditional iodine-131 in the treatment of metastatic and locally advanced differentiated thyroid cancer (EUDRACT) - Sep 20, 2024
P=N/A, N=150, Not yet recruiting, Sponsor: The Second Affiliated Hospital of Air Force Military Medical University; The Second Affiliated Hospital of Air Force Military Medical University
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma (EUDRACT) - Sep 20, 2024
P=N/A, N=21, Not yet recruiting, Sponsor: SUN YAT-SEN MEMORIAL HOSPITAL; SUN YAT-SEN MEMORIAL HOSPITAL
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Combination therapy, Metastases: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (EUDRACT) - Sep 20, 2024
P3, N=469, Recruiting, Sponsor: Zhongda Hospital Southeast University; Zhongda Hospital Southeast University
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A single arm, prospective, exploratory study of Adebrelimab combined with lenvatinib and hepatic arterial infusion chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma (EUDRACT) - Sep 20, 2024
P2, N=25, Not yet recruiting, Sponsor: Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
- |||| EG-007 / Evergreen Therap
Trial completion date, Trial primary completion date, Head-to-Head, Metastases: Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer (clinicaltrials.gov) - Sep 20, 2024
P3, N=450, Not yet recruiting, Sponsor: Evergreen Therapeutics, Inc.
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: LARENA: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=250, Recruiting, Sponsor: ARCAGY/ GINECO GROUP
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date: KEYNOTE-B61: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (clinicaltrials.gov) - Sep 19, 2024
P2, N=152, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026 Trial primary completion date: Aug 2024 --> Jan 2025
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study. (Pubmed Central) - Sep 19, 2024
Patient with infiltrative HCC, HAIC+Len+PD-1 treatment had longer OS and PFS than Len+PD-1 treatment. Early AFP response was an effective indicator of better survival and tumor response to therapy.
- |||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open: IMbrave251: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (clinicaltrials.gov) - Sep 19, 2024
P3, N=554, Recruiting, Sponsor: Hoffmann-La Roche
Early AFP response was an effective indicator of better survival and tumor response to therapy. Active, not recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial, Metastases: LENVAMEL: Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1 (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=18, Completed, Sponsor: Centre Hospitalier Universitaire de Besancon
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Sep 19, 2024
P2, N=343, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jun 2024
- | EG-007 / Evergreen Therap
Trial completion date, Trial primary completion date: Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (clinicaltrials.gov) - Sep 19, 2024
P2, N=28, Not yet recruiting, Sponsor: Evergreen Therapeutics, Inc.
Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jun 2024 Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Metastases: Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC (clinicaltrials.gov) - Sep 19, 2024
P2, N=23, Completed, Sponsor: Tianjin Medical University Second Hospital
Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026 Recruiting --> Completed | Trial completion date: Dec 2024 --> Sep 2024
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Review, Journal, Metastases: Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. (Pubmed Central) - Sep 18, 2024
Recruiting --> Completed | Trial completion date: Dec 2024 --> Sep 2024 The combination of TACE, Lenvatinib, and PD-1/L1 inhibitors appears to provide the maximum benefit for inoperable HCC patients.
- | Inlyta (axitinib) / Pfizer, Tracleer (bosentan) / J&J, Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical, Journal: Role of endothelin ET receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats. (Pubmed Central) - Sep 18, 2024
Bosentan, but not sitaxentan, also attenuated ET-1 mediated increases in HR. These data suggest that selective antagonists of ET receptors may be appropriate to alleviate the hypertensive effects of axitinib and lenvatinib.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1158;
P3
Conclusions Consistent with the global study population, 1L NIVO + IPI showed improvements in mOS and ORR vs LEN/SOR, with durable responses and manageable safety in Asian pts with uHCC. These results further support NIVO + IPI as a potential new 1L therapy for uHCC.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab (KCSG HB23-04) (Hall 406) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1157;
- Mekinist (trametinib) / Novartis, BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tafinlar (dabrafenib) / Novartis
Combining targeted therapy with conventional approach in advanced papillary thyroid cancer (PTC) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1115;
Checking for druggable molecular targets may provide a safer approach in treating patients with advanced thyroid cancer involving brain metastasis. Targeted therapies can be used safely in the neoadjuvant setting as well as help restore RAI avidity in the adjuvant setting in RAIR PTC.
- Case series of advanced cancer patients harboring FGFR3-TACC3 fusions detected by comprehensive genomic profiling (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1105;
In clinical practice, ctDNA or tumor NGS can detect rare and actionable FGFR3-TACC fusions in patients with advanced solid tumors that have progressed on standard therapy. Targeted therapy for such fusions can result in clinical benefit.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Immediate results of transarterial chemoembolization of hepatocellular carcinoma on the background of liver cirrhosis (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1099;
Complications included: arterial hypotension during the procedure in one (2.6%), liver abscess in one (2.6%), obstructive jaundice in one (2.6%) patient. The last two complications were resolved surgically.
- GRASSROOT: Global real-world data in patients with advanced thyroid cancer on standard of care and specialized interventions - Registry of oncologic outcomes with testing and treatment (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_772;
Pts with BRAFwt ATC tumors will be offered surgery followed by chemoradiation followed by adjuvant P or lenvatinib and P for stage IVC disease...To provide 90% power for a 0.67 hazard ratio, the study will enroll 459 patients over next 8 years at 14 national and international sites with an intended follow up of at least 2 years. The clinical trial was IRB at MDA approved in July 2024 and is in the process of opening other sites.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Real-world efficacy and safety of lenvatinib plus pembrolizumab in metastatic renal cell carcinoma patients with intermediate and poor risk (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_631;
Conclusions The ORR and PFS results of len+pembro were slightly lower than those observed in the prospective study, which may be explained by the more complex real-world patient population, with a higher number of poor risk patients, advanced disease, liver metastases, and sarcomatoid features. The treatment was well tolerated.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_620;
Conclusions Lenvatinib and pembrolizumab showed clinically meaningful efficacy in pts with bulky metastatic disease and non-clear cell histology. Older age and poor performance status were associated with lower response rate.
- Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of cadonilimab plus lenvatinib in previously immunotherapy treated advanced/metastatic clear cell renal cell carcinoma (ccRCC): A multicenter, single-arm, phase II trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_614;
P2
Cadonilimab plus lenvatinib showed encouraging anti-tumor activity and manageable safety profile. This study is ongoing and further exploration is necessary.
- Keytruda (pembrolizumab) / Merck (MSD)
Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06 substudy 06B (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_610;
P1/2
This study is ongoing and further exploration is necessary. Patients will be assigned to treatment arms 1 or 4: investigator's choice of chemotherapy (paclitaxel 80-100 mg/m 2 IV days 1, 8, and 15 of every 28-day cycle or irinotecan 180 mg/m 2 day 1 of every 14-day cycle) (arm 1; ?30 patients) or sacituzumab tirumotecan (also known as MK-2870/SKB264; trophoblast antigen 2
- Tevimbra (tislelizumab-jsgr) / BeiGene
Efficacy and safety of transarterial chemoembolization (TACE) in combination with tislelizumab and TKIs versus TACE for the treatment of Intermediate and advanced HCC: A retrospective cohort study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_585;
Table: 240P Baseline characteristics Characteristics TACE+Tislelizumab+TKIs (n=30) TACE (n=32) P value Median age (range), years 55 (30-75) 60.5 (36-78) 0.409 Male, n(%) 28 (93.3) 29 (90.6) 1.000 BCLC stage, n(%), B/C 16 (53.3)/14 (46.7) 16 (50.0)/16 (50.0) 0.805 ECOG PS, n(%), 0/1 26 (86.7)/4 (13.3) 27 (84.4)/5 (15.6) 1.000 Child-Pugh, n(%), A/B 19 (63.3)/11 (36.7) 24 (75.0)/8 (25.0) 0.411 MVI present, n(%) 11 (36.7) 16 (50.0) 0.317 EHS present, n(%) 7 (23.3) 7 (21.9) 1.000 Median number of TACE 3 2 0.399 Conclusions Compared to TACE, TACE combined with tislelizumab and TKIs is expected to be a safe and effective treatment for intermediate and advanced HCC. The combined therapy could be regarded as a considerable option for conversion strategy in this population.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Characteristics and prognosis of primary and acquired resistance to immune checkpoint inhibitors combination treatment in unresectable hepatocellular carcinoma (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_581;
Methods Unresectable HCC patients treated with ICI and Lenvatinib were included in this retrospective study...Primary and acquired resistance have strong impact toward overall survival. There exists significant difference in risk factors for survival in uHCC patients with primary and acquired resistance.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Outcomes with first-line therapy and impact of ALBI grade in advanced hepatocellular carcinoma: Insights from a lower-middle-income country (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_565;
Conclusions The ALBI grade, simpler and more objective than the Child-Pugh score, is a valuable prognostic tool for HCC patients. As assessed by ALBI, Lenvatinib shows a survival advantage over sorafenib and atezolizumab/bevacizumab, particularly in patients with better-preserved liver function.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Long-term outcomes of a multicenter phase II trial evaluating the efficacy of preoperative lenvatinib therapy for patients with advanced hepatocellular carcinoma (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_561;
At the time of the survey, 13 patients were alive without cancer. Conclusions Even in patients with HCC accompanied by factors suggestive of a poor prognosis, the long-term outcomes of patients who underwent lenvatinib therapy followed by surgical resection were relatively favorable.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Atezolizumab plus bevacizumab versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma: A large real-life worldwide population (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_555;
Favorable prognostic factors for TTP in the A+B cohort were in TACE refractory patients (HR 0.76, p=0.02), PLT <100.000 (HR 0.62, p=0.0067), and Neutrophil-to-lymphocyte ratio (NLR) <3 (HR 0.78, p=0.04). Conclusions The study showed a greater response of Lenvatinib and no statistically significant differences between Lenvatinib and A+B in terms of efficacy.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: A phase II trial (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_554;
P2
Most adverse events were grade 1 or 2, including epigastric pain, low-grade fever, short-term liver function damage, and thrombocytopenia. Conclusions HAIC sequential TAE combined with lenvatinib and tislelizumab was well tolerated and found to have a promising efficacy in patients with high-risk unresectable HCC.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion tislelizumab and chemotherapy plus DEB-TACE in combination with lenvatinib for first-line treatment of unresectable HCC: A prospective, single arm, phase II study (HAITC study) (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_547;
Only 1 (5%) pt reported Grade 3-4 TRAEs (AST/ALT elevated and hypoalbuminemia). Conclusions In this study, hepatic arterial infusion tislelizumab and chemotherapy plus DEB-TACE in combination with Lenvatinib showed potential efficacy and acceptable safety for first line treatment of unresectable HCC.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: Updated efficacy and safety results from the phase II NeoLEAP-HCC study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_546;
P2
Conclusions Perioperative pembrolizumab and lenvatinib appears to be safe and beneficial in DFS in pts with resectable HCC. The results support further investigation of perioperative immunotherapy for HCC.
- Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of lenvatinib plus adebrelimab combined with hepatic arterial infusion chemotherapy (HAIC) for unresectable biliary tract cancer (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_542;
In this study, we determined the preliminary clinical efficacy and safety of lenvatinib plus adebrelimab in combination with the GEMOX-HAIC (hepatic arterial infusion chemotherapy with gemcitabine, and oxaliplatin) in patients with previously untreated uBTC...Table: 197P Characteristics Patients(n=41) Gender Male 27 (65.9%) Female 14 (34.1%) Age, Mean (SD), year 59.38 (1.8) ?65 14 (34.1%) 5 33 (80.5%) Tumor number Single 15 (36.6%) Multiple 26 (63.4%) Vascular Invasion Absence 14 (34.1%) Presence 27 (65.9%) LN metastasis Absence 17 (41.5%) Presence 24 (58.5%) Distant metastasis Absence 34 (82.9%) Presence 7 (17.1%) TNM stage I 2 (4.9%) II 5 (12.2%) IIIa 6 (14.6%) IIIb 19 (46.3%) IV 9 (22.0%) CA19-9, U/mL ?40 17 (41.5%) >40 24 (58.5%) Conclusions Lenvatinib plus adebrelimab combined with GEMOX-HAIC showed promising antitumor activity and manageable AEs inpatients with treatment-naive uBTC. This regimen may be suitable as a novel first-line treatment option for this patient population.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Efficacy of ipilimumab plus nivolumab therapy in patients having hepatocellular carcinoma with main portal vein invasion (Vp4): Multicenter real-world study (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_501;
50% had significantly shorter OS than those with <50% infiltration (2.0 vs. 15.8 months, p < 0.001). Conclusions Main portal vein tumor thrombus may not affect the survival of patients treated with Ipi/Nivo for advanced HCC.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and its impact on overall survival of transarterial chemoembolization (TACE) combined with Lenvatinib in hepatocellular carcinoma patients belonging to BCLC stage C (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_500;
Of 26 patients, 57.7% showed partial response, 30.8% showed stable disease, and 11.5% showed progressive disease. Conclusions Patients with BCLC stage C treated with TACE combined with lenvatinib had significant survival benefits and significantly prolonged the overall survival time of these patients with a good safety profile.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib demonstrates enhanced efficacy in IDH1-mutated cholangiocarcinoma with hyper vascular features on abdominal CT (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_487;
Conclusions Lenvatinib could be a safe and cost-effective treatment for metastatic/advanced CCA, particularly in patients with IDH-1 mutations. Among IDH-1 mutated cases, those with tumor hypervascularity on abdominal CT scans demonstrated an even more favorable treatment response to lenvatinib.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Tumor microenvironment: A versatile nanoplatform carrying cascade Pt nanozymes remodeling tumor microenvironment for amplified sonodynamic/chemo therapy of thyroid cancer. (Pubmed Central) - Sep 15, 2024
To overcome this dilemma, we developed a pH-responsive biomimetic nanocarrier (CLP@HP-A) through the incorporation of Chlorin e6 (Ce6) and Lenvatinib (Len) within hollow polydopamine nanoparticles (HP) that were further modified with platinum nanoparticles (Pt), enabling synergistic chemotherapy and sonodynamic therapy...Transcriptomics analysis findings additionally corroborated that CLP@HP-A effectively triggered cancer cell apoptosis, thereby serving as a crucial mechanism for its cytotoxic effects. In conclusion, the integration of sonodynamic/chemo combination therapy with targeted drug delivery systems offers a novel approach to the management of malignant tumors.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study. (Pubmed Central) - Sep 15, 2024
In conclusion, the integration of sonodynamic/chemo combination therapy with targeted drug delivery systems offers a novel approach to the management of malignant tumors. Camrelizumab plus TACE and sorafenib or lenvatinib may be a promising treatment approach for the clinical management of unresectable HCC patients.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Injectable Hydrogel-Encapsulating Pickering Emulsion for Overcoming Lenvatinib-Resistant Hepatocellular Carcinoma via Cuproptosis Induction and Stemness Inhibition. (Pubmed Central) - Sep 14, 2024
In vivo and in vitro LenR HCC models demonstrated significant therapeutic efficacy. In conclusion, this novel approach underscores DSF@CuO Gel's potential to overcome LenR in HCC, offering a novel approach to address this clinical challenge.
- | Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma. (Pubmed Central) - Sep 14, 2024
In conclusion, we identified small molecules that can be further exploited experimentally in HCC therapeutics. Our study also demonstrated the use of the MDeePred deep learning tool in in silico drug repurposing efforts for cancer therapeutics.
- || Review, Journal: Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies. (Pubmed Central) - Sep 14, 2024
This study provides comprehensive insights into effective treatment interventions for HCC in Asian populations. The overall assessment indicates that sorafenib, used alone or in combination with atezolizumab and bevacizumab, has been the first treatment choice in the past decade to achieve better outcomes in patients with HCC in Asian populations.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
P1 data, Journal: A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma. (Pubmed Central) - Sep 12, 2024
P1a/1b
Nofazinlimab was well tolerated in Chinese patients. Preliminary efficacy was encouraging, particularly for nofazinlimab plus lenvatinib in uHCC, which is being studied in an ongoing phase 3 trial.
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Retrospective data, Review, Journal: Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta?analysis. (Pubmed Central) - Sep 12, 2024
LEN has advantages in improving the OS of patients with grade B liver function. However, more multicenter randomized controlled experiments are needed in the future to verify our results.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Combination therapy, Metastases: Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma. (Pubmed Central) - Sep 12, 2024
Multifactorial Cox analysis revealed that EOS3 was an independent predictor of PFS and that EOS0 was an independent predictor of OS (P?<?0.05). EOS may be an ideal indicator for predicting the treatment efficacy and prognosis of patients with advanced HBV-HCC receiving C?+?L.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
MYOPATHY LEADING TO RHABDOMYOLYSIS AS A RARE SIDE EFFECT OF LENVATINIB AND PEMBROLUZIMAB THERAPY (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_5900;
Myositis and rhabdomyolysis have also been reported in the literature as a rare side effect in anti-PDL-1 drugs, such as pembrolizumab, and anti-CTLA-4 drugs, such as ipilimumab.[3,4] One proposed mechanism to this process is new autoimmune hypothyroidism leading to rhabdomyolysis.[5] In patients who are on both TKI's and ICI's, it may be difficult to discern the instigating agent as illustrated in this case report...Prior to admission, she was taking amlodipine, diazepam, glipizide, Lantus, levothyroxine, lisinopril-hydrochlorothiazide, metformin, rosuvastatin, pembrolizumab, and lenvatinib for several months... Serial CK levels can be useful in patients presenting to the clinic with muscle pain or weakness.7 Routine screening for musculoskeletal symptoms in patients on TKI's and ICI's should be a part of regular follow up.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions. (Pubmed Central) - Sep 10, 2024
There was no significant difference in AE rates between the reference and study products. The study determined that both the study product and the reference product were bioequivalent and well tolerated by healthy Chinese participants in both fasting and postprandial conditions.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. (Pubmed Central) - Sep 10, 2024
The objectives of this multiple technology appraisal were to appraise the clinical effectiveness and cost-effectiveness of lenvatinib plus pembrolizumab versus relevant comparators listed in the final scope issued by the National Institute for Health and Care Excellence: sunitinib, pazopanib, tivozanib, cabozantinib and nivolumab plus ipilimumab...49. See the NIHR Funding and Awards website for further award information.
- ||| Journal, Adverse events, Real-world evidence, Real-world: Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. (Pubmed Central) - Sep 9, 2024
Further classifying the 164 antineoplastic agents into 46 chemical subgroups to conduct ADR signal detection, nitrogen mustard analogs were the most reported antineoplastic agent subclasses, followed by clusters of differentiation 20 inhibitors, and pyrimidine analogs, while clusters of differentiation 22 inhibitors were the antineoplastic agent subclass with the highest ADR signal strength, followed by podophyllotoxin derivatives and actinomycines. Our study showed the TLS risk characteristics of 164 antineoplastic agents by detecting and integrating ADR signals, which may help to optimize clinical practice.
- E7386 / Eisai, PRISM Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
E7386 enhances both lenvatinib and anti-PD1 antitumor activity in HCC (Exhibition Hall) - Sep 7, 2024 - Abstract #EORTCNCIAACR2024EORTC_NCI_AACR_141;
Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 9 October 2024. All other abstracts will be released on the day of presentation.